How much funding has IgGenix raised?

IgGenix has raised $75.0M in total funding, most recently a series b round.

Who are IgGenix's investors?

IgGenix's investors include Khosla Ventures, Alexandria Venture Investments, Matthias Westman, AllerFund, Eli Lilly and Company, Sean Parker.

Where is IgGenix headquartered?

IgGenix is headquartered in San Francisco Bay Area, California, United States.

IgGenix

Solving allergies with precision antibody engineering

San Francisco Bay Area, United States · Founded 2019 · $75.0M raised

Biotech

Headquarters: San Francisco Bay Area, California
Employees: 11–50
Founded: 2019
Business Model: B2B

Website: iggenix.com
Total Funding: $75.0M
Last Round: $40.0M Series BFeb 2023
Rounds: 3

About

IgGenix is a clinical-stage antibody discovery and development company using its proprietary SEQ SIFTER single-cell RNA-sequencing platform to identify and re-engineer rare human IgE antibodies into high-affinity IgG4 therapeutics. Its lead program, IGNX001, targets peanut allergy and has completed Phase 1 enrollment; the pipeline also includes food, environmental, and atopic disease programs.

Summary

IgGenix is a Biotech company based in San Francisco Bay Area, United States, founded in 2019. It has raised $75.0M in total across 3 rounds, most recently a $40.0M Series B round in Feb 2023. Investors include Khosla Ventures, Alexandria Venture Investments and Matthias Westman.

LinkedIn X (Twitter)